Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 0.50 |
| ▸ | DRD3 | P35462 | 17/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391664 | 0.78 | DRD2 (0.51) | DRD2DRD3 | |
| SCHEMBL6179277 | 0.78 | DRD2 (0.51) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL392430 | 0.77 | DRD2 (0.51) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL388277 | 0.77 | DRD2 (0.51) | DRD2DRD3 | |
| SCHEMBL4391031 | 0.77 | DRD2 (0.49) | DRD2DRD3GRIN2B | |
| SCHEMBL16463637 | 0.76 | DRD2 (0.58) | DRD2DRD3 | |
| SCHEMBL392181 | 0.76 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL4390731 | 0.76 | GRIN2B (0.47) | DRD2DRD3GRIN2B | |
| SCHEMBL4608344 | 0.75 | GRIN2B (0.51) | DRD2DRD3GRIN2AGRIN2B | |
| SCHEMBL391907 | 0.75 | DRD2 (0.55) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272187-B1 | DOPAMINE-D3 RECEPTOR LIGANDS FOR THE TREATMENT OF ADDICTION | ABBOTT GMBH & CO KG (DE) | 2008-07-30 | — | — | EP | claimed |
| EP-1272187-B1 | DOPAMINE-D3 RECEPTOR LIGANDS FOR THE TREATMENT OF ADDICTION | ABBOTT GMBH & CO KG (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-20030087917-A1 | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087917-A1 | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system | DRD3, DRD2, OPRD1 | DRD2 2/4885DRD3 1/4885GRIN2A 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.